Atogepant for the Preventive Treatment of Episodic Migraine

Atogepant is FDA approved for the prevention of episodic migraine, and is under review for the prevention of chronic migraine at the time of publication. Stay tuned as Dr. Cynthia E. Armand discusses the goals of migraine prevention, atogepant clinical trial data, how it compares to other gepant medications, side effects, and more.

*The contents of this podcast are intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. AMD and the speaker do not recommend or endorse any specific course of treatment, products, procedures, opinions, or other information that may be mentioned. Reliance on any information provided by this content is solely at your own risk.